In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Aligos Therapeutics, with a price target of $50.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Aligos Therapeutics’ strong position in the field of liver disease treatment. The company’s focus on chronic hepatitis B virus (HBV) and metabolic dysfunction-associated steatohepatitis (MASH) has shown promising results, with their lead programs demonstrating significant potential. The management’s confidence and data-driven approach, as presented during the non-deal roadshow, underscore the company’s strategic positioning and execution capabilities.
Aligos’ lead drug, pevifoscorvir sodium, is positioned to potentially replace standard treatments for chronic HBV due to its rapid and durable viral clearance and high barrier to resistance. Additionally, ALG-055009 has shown strong efficacy and safety in Phase 2 trials, attracting interest for potential partnerships. With a solid cash position projected to last into the third quarter of 2026 and multiple upcoming milestones, Trucchio believes Aligos is well-positioned to maintain its leadership in liver disease innovation, justifying the Buy rating and a price target of $50.